Treatment of tobacco addiction by a tobacco leaf extract
The invention relates to a tobacco leaf extract containing, relative to the total weight of the extract, at least 5 wt.-% proteins essentially free of molecules with a molecular mass of less than 10 kDa. The invention also relates to a pharmaceutical composition containing such an extract and to the use thereof in the treatment of tobacco addiction.
1. A method for treatment of tobacco addiction comprising administering to a patient in need thereof an effective amount of a tobacco leaf extract or a composition comprising a tobacco leaf extract;
wherein the tobacco leaf extract contains at least 5% by weight, based on the total weight of the dry extract, of proteins of molecular mass greater than 10 kDa, and is essentially free of molecules of molecular mass less than 10 kDa;
wherein the content, in the tobacco leaf extract, of proteins whose molecular mass is greater than 500 kDa is less than 15% by weight, based on the total protein weight of the extract.
2. The method for treatment according to claim 1 , wherein the proteins are selected from the group consisting of the following protein families: lignin-forming anionic peroxidase, glucan endo-1,3-beta-glucosidase, endochitinase, pathogenesis-related protein, osmotin, proteinase inhibitors, and mixtures thereof.
3. The method for treatment according to claim 1 , wherein the content, in the tobacco leaf extract, of proteins whose molecular mass is greater than 100 kDa is less than 15% by weight based on the total protein weight of the extract.
4. The method for treatment according to claim 1 , wherein the tobacco leaf extract comprises at least one protein belonging to the family of glucan endo-1,3-beta-glucosidases selected from the group consisting of beta-1,3-endoglucanase acidic isoform PR-Q′ (PR36401 according to the UniProt database), beta-1,3-endoglucanase basic vacuolar isoform GLB (P27666 according to the UniProt database), and mixtures thereof.
5. The method for treatment according to claim 1 , wherein the tobacco leaf extract comprises at least one protein belonging to the family of endochitinases selected from the group consisting of acidic endochitinase P (P17513 according to the UniProt database), acidic endochitinase Q (P17514 according to the UniProt database), endochitinase B (P24091 according to the UniProt database), and mixtures thereof.
6. The method for treatment according to claim 1 , wherein the tobacco leaf extract comprises at least osmotin (P14170 according to the UniProt database).
7. The method for treatment according to claim 1 , wherein the tobacco leaf extract comprises at least one lignin-forming anionic peroxidase (P11965 according to the UniProt database).
8. The method for treatment according to claim 1 , wherein the tobacco leaf extract comprises at least one pathogenesis-related protein selected from the group consisting of pathogenesis-related protein R (P13046 according to the UniProt database), pathogenesis-related protein PR-4A (PR29062 according to the UniProt database), pathogenesis-related protein PR-4B (PR29063 according to the UniProt database), and mixtures thereof.
9. The method for treatment according to claim 1 , wherein the tobacco leaf extract comprises at least one protein belonging to the family of proteinase inhibitors selected from the group consisting of proteinase inhibitor I-B (Q03199 according to the UniProt database), proteinase inhibitor I-A (Q03198 according to the UniProt database), and mixtures thereof.
10. The method for treatment according to claim 1 , wherein the protein content in the dry extract of the tobacco leaf extract is at least 10% by weight based on the total weight of the dry extract.
11. The method for treatment according to claim 1 , wherein the proteins present in the tobacco leaf extract are present in an amount ranging from 1 to 1 000 μg/mL.
12. The method for treatment according to claim 1 , wherein the tobacco leaf extract or the composition is provided in a form suitable for administration by subcutaneous injection, in a form suitable for administration by means of an adhesive transdermal therapeutic system, or in a form suitable for administration by spraying or by vaporization.
13. The method for treatment according to claim 1 , wherein the tobacco leaf extract or the composition is provided in a dosage form of 0.03 mL to 10 mL.
14. The method for treatment according to claim 1 , wherein the tobacco leaf extract is essentially free of RuBisCO.